ClinicalTrials.gg
TerminatedNCT00823433Updated Nov 4, 2016

Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood

An Early Phase 1 interventional study of oral penicillin V in Group B Streptococcus, sponsored by Corewell Health East. Terminated at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-04.

Sponsored by Corewell Health East · Early Phase 1, Interventional, and Prevention

Why this study was terminated
Insufficient enrollment.
Phase
Early Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Pregnant,laboring women will receive 2 grams of oral penicillin V before delivery. At the time of delivery of the infant, umbilical vein cord blood will be obtained from the umbilical cord. These cord blood samples will be sent for bioassay of penicillin levels.

Read the detailed description

According to the CDC, before screening for GBS colonization was implemented, early onset GBS disease occurred at a rate of 1.5-2 per 1,000 live births. Antibiotic treatment for GBS colonized women according to guideline recommended by the American College of Obstetricians and Gynecologists (ACOG) decreases the risk for early onset neonatal GBS infection 10 fold. Unfortunately, many eligible women don't receive the full treatment protocol. Although the rate of early onset infection is low, the newborns of group B strep positive women who do not receive the recommended preventative antibiotics must undergo testing and extended observation.

This study will determine the level of antibiotics in the umbilical vein cord blood of newborn infants after the administration of penicillin orally while in labor and compare these levels to levels of penicillin in the umbilical vein cord blood of patients treated with intravenous penicillin in labor. Comparisons will be done through literature only; there will be no intravenous penicillin administration arm of the study.

02

Conditions studied

  • Group B Streptococcus

Keywords

  • Penicillin
  • Group B Streptococcus
  • Pregnancy
  • Labor
03

In context

Lead sponsor

Corewell Health East is the lead sponsor of 19 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pregnant women admitted for delivery or for induction of labor
  • singleton pregnancy
  • 18 years old or older
  • beyond 36 weeks gestation
  • able to comprehend study and give informed consent

Exclusion criteria

Exclusion Criteria:

  • known history of beta-lactam antibiotic allergy
  • impaired renal function
  • multiple gestation
  • current use of antibiotics
  • plan to bank cord blood after delivery
05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Oral Penicillin

    2 grams of oral penicillin V given within 4 hours of delivery

    Drug: oral penicillin V

Interventions

06

What researchers measure

Primary outcomes

  1. The level of antibiotics in the umbilical vein cord blood of newborn infants after the administration of penicillin orally while in labor.

    Time frame: after delivery

Secondary outcomes

  1. Compare levels of penicillin in the umbilical cord blood of women who received oral penicillin to the levels of women who received intravenous penicillin in labor. Comparisons will be done through literature only.

    Time frame: after delivery

07

Study locations

1 site
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00823433
Lead sponsor
Corewell Health East
Responsible party
John Uckele (Attending Physician, Corewell Health East) — Principal investigator
First posted
Jan 15, 2009
Start date
Jan 2009
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Nov 4, 2016

Study contacts

John E Uckele, MD
principal investigator · Corewell Health East

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Penicillin V

Start the discussion